2024 European Breast Cancer Conference

By Caroline Helwick / September 2024 / 2024 European Breast Cancer Conference

Phase III ALEXANDRA/IMpassion030: No Survival Benefit for Adjuvant Atezolizumab in Triple-Negative Breast Cancer

In patients with early-stage triple-negative breast cancer, the addition of atezolizumab to standard adjuvant chemotherapy provided no benefit over chemotherapy alone in the final analysis of the phas...

Breast Cancer

Genomics/Genetics

By Caroline Helwick / July 25, 2024 / 2024 European Breast Cancer Conference

New Genetic Test May Predict Response to Immunotherapy in Triple-Negative Breast Cancer

The search for biomarkers of response to immunotherapy is high on the list of cancer-related research efforts. A new classifier in triple-negative breast cancer is showing promise and is currently bei...

2024 European Breast Cancer Conference

Phase III ALEXANDRA/IMpassion030: No Survival Benefit for Adjuvant Atezolizumab in Triple-Negative Breast Cancer

New Genetic Test May Predict Response to Immunotherapy in Triple-Negative Breast Cancer

IASLC: Taletrectinib in ROS1-Positive NSCLC

FDA Approves Atezolizumab and Hyaluronidase-tqjs for Subcutaneous Injection

NeoCOAST 2 Trial Durvalumab Plus Novel Agents May Increase Pathologic Responses in Resectable NSCLC

FDA Seeks Consumer Representatives for ODAC

Using TROP2 Expression to Predict Outcomes in Advanced NSCLC